| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Basic Science Investigations |
-Receptor Ligands, 18F-FE-SA5845 and 11C-SA4503: A Feasibility Study
1 PET Center, Groningen University Hospital, Groningen, The Netherlands
2 Department of Medical Oncology, Groningen University Hospital, Groningen, The Netherlands
3 Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
4 M’s Science, Kobe, Japan
Our objective was to study 2 radioligands for visualization of 
-receptors with PET. Methods: Two radioligands—1-selective 11C-1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine (11C-SA4503) and nonsubtype-selective 1-(4–2'-18F-fluoroethoxy-3-methoxyphenethyl)-4-(3-(4-fluorophenyl)propyl)piperazine (18F-FE-SA5845)—were evaluated for tumor imaging. Results: Binding studies to rat glioma cells (C6) and human nonsmall cell lung cancer cells (N417) indicated interaction of 18F-FE-SA5845 with 2 sites and interaction of 11C-SA4503 with a single site. Specific binding of 18F-FE-SA5845 was 93% ± 2% and that of 11C-SA4503 was 78% ± 6% of the total cellular uptake of radioactivity. Uptake of the 18F-labeled ligand, but not that of the 11C-labeled ligand, appeared to be related to the growth phase of the cells. Biodistribution experiments in C6 tumor-bearing nude rats (Ham HSD RNU rnu) indicated tumor-to-plasma ratios of 13.3 for 11C-SA4503 and 8.0 for 18F-FE-SA5845 and tumor-to-muscle ratios of 5.0 for 11C-SA4503 and 4.9 for 18F-FE-SA5845, 60 min after injection, which were reduced to values ranging from 1.4 to 2.0 after pretreatment of animals with haloperidol (2 µmol/kg). Tumor uptake of 18F-FE-SA5845 showed a negative correlation with tumor size (P < 0.0001), in contrast to that of 11C-SA4503, suggesting that tissue binding of the former ligand is related to cellular proliferation. A study with 11C-SA4503 in a human volunteer indicated high uptake in liver, kidney, and heart but relatively low background in thorax and lower abdomen. Conclusion: Both 18F-FE-SA5845 and 11C-SA4503 demonstrate specific binding to -receptors in vivo and may be useful for the detection of pulmonary and abdominal tumors. However, the 18F-labeled compound may be better for tumor staging than the 11C-labeled drug.
Key Words: tumor imaging • PET • -receptors • cellular proliferation • SA4503
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  A. van Waarde, K. Shiba, J. R. de Jong, K. Ishiwata, R. A. Dierckx, and P. H. Elsinga Rapid Reduction of {sigma}1-Receptor Binding and 18F-FDG Uptake in Rat Gliomas After In Vivo Treatment with Doxorubicin J. Nucl. Med., August 1, 2007; 48(8): 1320 - 1326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Renaudo, S. L'Hoste, H. Guizouarn, F. Borgese, and O. Soriani Cancer Cell Cycle Modulated by a Functional Coupling between Sigma-1 Receptors and Cl- Channels J. Biol. Chem., January 26, 2007; 282(4): 2259 - 2267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. van Waarde, L. B. Been, K. Ishiwata, R. A. Dierckx, and P. H. Elsinga Early Response of {sigma}-Receptor Ligands and Metabolic PET Tracers to 3 Forms of Chemotherapy: An In Vitro Study in Glioma Cells J. Nucl. Med., September 1, 2006; 47(9): 1538 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Rowland, Z. Tu, J. Xu, D. Ponde, R. H. Mach, and M. J. Welch Synthesis and In Vivo Evaluation of 2 High-Affinity 76Br-Labeled {sigma}2-Receptor Ligands J. Nucl. Med., June 1, 2006; 47(6): 1041 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. van Waarde, P. L. Jager, K. Ishiwata, R. A. Dierckx, and P. H. Elsinga Comparison of Sigma-Ligands and Metabolic PET Tracers for Differentiating Tumor from Inflammation J. Nucl. Med., January 1, 2006; 47(1): 150 - 154. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
